Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Bupre… (NCT07202039) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
United States90 participantsStarted 2026-04-29
Plain-language summary
This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
Who can participate
Age range21 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria
* Age ≥21 years
* Smoke ≥5 CPD for ≥1 year
* Daily CC smoker
* Willing to switch to EC
* Exhaled CO ≥6 ppm
* Diagnosed with OUD
* Stable on bupropion treatment
* In good physical and mental health
* Able to use a smartphone
* Willing to participate in all study components
* Able to provide informed consent Exclusion Criteria
* Interested in quitting CC (contemplation stage of change)
* Use of EC on ≥4 of the past 30 days
* Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days
* Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days
* Hypertension
* Medical condition that would contraindicate participation
* Meet DSM-V criteria for major depressive episode, psychotic episode, or manic episode
* Current suicidal ideation or suicide attempt in the past year
* Psychiatric hospitalization in the past year
* Contemplating pregnancy, currently pregnant, or breastfeeding
* Unable to speak and/or read English